{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:54:35Z","timestamp":1793235275406,"version":"4.5.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Clinics of North America: Small Animal Practice"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cvsm.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T16:17:14Z","timestamp":1688487434000},"page":"1293-1308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Advancing Treatments for Feline Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"53","author":[{"given":"Joanna L.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor N.","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cvsm.2023.05.011_bib1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/jvim.15745","article-title":"ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats","volume":"34","author":"Fuentes","year":"2020","journal-title":"J\u00a0Vet Intern Med"},{"issue":"11","key":"10.1016\/j.cvsm.2023.05.011_bib2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1177\/1098612X211020162","article-title":"The feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy","volume":"23","author":"Kittleson","year":"2021","journal-title":"J\u00a0Feline Med Surg"},{"issue":"5","key":"10.1016\/j.cvsm.2023.05.011_bib3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1939-1676.1991.tb03134.x","article-title":"Evaluation of the calcium channel-blocking agents diltiazem and verapamil for treatment of feline hypertrophic cardiomyopathy","volume":"5","author":"Bright","year":"1991","journal-title":"J\u00a0Vet Intern Med"},{"issue":"5","key":"10.1016\/j.cvsm.2023.05.011_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0195-5616(91)50110-8","article-title":"Evidence for or against the efficacy of calcium channel blockers for management of hypertrophic cardiomyopathy in cats","volume":"21","author":"Bright","year":"1991","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"2","key":"10.1016\/j.cvsm.2023.05.011_bib5","first-page":"93","article-title":"Effect of treatment with atenolol on 5-year survival in cats with preclinical (asymptomatic) hypertrophic cardiomyopathy","volume":"15","author":"Schober","year":"2013","journal-title":"J\u00a0Vet Cardiol"},{"key":"10.1016\/j.cvsm.2023.05.011_bib6","first-page":"77","article-title":"Atenolol in cats with subclinical hypertrophic cardiomyopathy: a double-blind, placebo-controlled, randomized clinical trial of effect on quality of life, activity, and cardiac biomarkers","volume":"30","author":"Coleman","year":"2020","journal-title":"J\u00a0Vet Cardiol"},{"issue":"5","key":"10.1016\/j.cvsm.2023.05.011_bib7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1939-1676.2006.tb00707.x","article-title":"The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure","volume":"20","author":"MacDonald","year":"2006","journal-title":"J\u00a0Vet Intern Med"},{"issue":"2","key":"10.1016\/j.cvsm.2023.05.011_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1939-1676.2008.0049.x","article-title":"Effect of spironolactone on diastolic function and left ventricular mass in Maine Coon cats with familial hypertrophic cardiomyopathy","volume":"22","author":"MacDonald","year":"2008","journal-title":"J\u00a0Vet Intern Med"},{"issue":"1","key":"10.1016\/j.cvsm.2023.05.011_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5326\/15473317-34-1-38","article-title":"The use of enalapril in the treatment of feline hypertrophic cardiomyopathy","volume":"34","author":"Rush","year":"1998","journal-title":"J\u00a0Am Anim Hosp Assoc"},{"issue":"6","key":"10.1016\/j.cvsm.2023.05.011_bib10","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1111\/jvim.15572","article-title":"Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo-controlled clinical trial","volume":"33","author":"King","year":"2019","journal-title":"J\u00a0Vet Intern Med"},{"issue":"2","key":"10.1016\/j.cvsm.2023.05.011_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5326\/0410098","article-title":"Evaluation of extended-release diltiazem once daily for cats with hypertrophic cardiomyopathy","volume":"41","author":"Wall","year":"2005","journal-title":"J\u00a0Am Anim Hosp Assoc"},{"issue":"1","key":"10.1016\/j.cvsm.2023.05.011_bib12","first-page":"19","article-title":"Effects of benazepril in the treatment of feline hypertrophic cardiomyopathy results of a prospective, open-label, multicenter clinical trial","volume":"1","author":"Amberger","year":"1999","journal-title":"J\u00a0Vet Cardiol"},{"issue":"9","key":"10.1016\/j.cvsm.2023.05.011_bib13","doi-asserted-by":"crossref","first-page":"e024656","DOI":"10.1161\/JAHA.121.024656","article-title":"Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter","volume":"11","author":"Masri","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.cvsm.2023.05.011_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jvp.13103","article-title":"Pharmacokinetics of a single dose of aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model","volume":"46","author":"Sharpe","year":"2023","journal-title":"J\u00a0Vet Pharmacol Therap"},{"issue":"3","key":"10.1016\/j.cvsm.2023.05.011_bib15","first-page":"433","article-title":"A\u00a0one health approach to hypertrophic cardiomyopathy","volume":"90","author":"Ueda","year":"2017","journal-title":"Yale J Biol Med"},{"issue":"9","key":"10.1016\/j.cvsm.2023.05.011_bib16","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1161\/01.CIR.92.9.2645","article-title":"Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy. An animal model of human disease","volume":"92","author":"Fox","year":"1995","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.cvsm.2023.05.011_bib17","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/bph.15484","article-title":"Transgenic rabbit models for cardiac disease research","volume":"179","author":"Hornyik","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.cvsm.2023.05.011_bib18","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1038\/s41598-018-22936-z","article-title":"Successful knock-in of hypertrophic cardiomyopathy-mutation R723G into the MYH7 gene mimics HCM pathology in pigs","volume":"8","author":"Montag","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.cvsm.2023.05.011_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0034-5288(02)00189-3","article-title":"Structural and biochemical evidence of mitochondrial depletion in pigs with hypertrophic cardiomyopathy","volume":"74","author":"Lin","year":"2003","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.cvsm.2023.05.011_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.yjmcc.2021.04.009","article-title":"Translational investigation of electrophysiology in hypertrophic cardiomyopathy","volume":"157","author":"Flenner","year":"2021","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"2\u20133","key":"10.1016\/j.cvsm.2023.05.011_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcpa.2010.12.003","article-title":"An immunohistochemical study of feline myocardial fibrosis","volume":"145","author":"Aupperle","year":"2011","journal-title":"J\u00a0Comp Pathol"},{"issue":"4","key":"10.1016\/j.cvsm.2023.05.011_bib22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0300985819837717","article-title":"Feline hypertrophic cardiomyopathy: che Consequence of cardiomyocyte-initiated and macrophage-driven remodeling processes?","volume":"56","author":"Kitz","year":"2019","journal-title":"Vet Pathol"},{"issue":"4","key":"10.1016\/j.cvsm.2023.05.011_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.14740\/cr578w","article-title":"Feline hypertrophic cardiomyopathy: a spontaneous large animal model of human HCM","volume":"8","author":"Freeman","year":"2017","journal-title":"Cardiol Res"},{"issue":"12","key":"10.1016\/j.cvsm.2023.05.011_bib24","doi-asserted-by":"crossref","first-page":"e0168407","DOI":"10.1371\/journal.pone.0168407","article-title":"A\u00a0small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.cvsm.2023.05.011_bib25","first-page":"S6","article-title":"Hypertrophic cardiomyopathy in man and cats","volume":"17","author":"Maron","year":"2015","journal-title":"J\u00a0Vet Cardiol"},{"key":"10.1016\/j.cvsm.2023.05.011_bib26","doi-asserted-by":"crossref","first-page":"105176","DOI":"10.1016\/j.phrs.2020.105176","article-title":"Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy","volume":"160","author":"Santini","year":"2020","journal-title":"Pharmacol Res"},{"issue":"Suppl 1","key":"10.1016\/j.cvsm.2023.05.011_bib27","first-page":"S53","article-title":"The genetic basis of hypertrophic cardiomyopathy in cats and humans","volume":"17","author":"Kittleson","year":"2015","journal-title":"J\u00a0Vet Cardiol"},{"issue":"3","key":"10.1016\/j.cvsm.2023.05.011_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12265-011-9266-2","article-title":"How do mutations in contractile proteins cause the primary familial cardiomyopathies?","volume":"4","author":"Marston","year":"2011","journal-title":"J\u00a0Cardiovasc Transl Res"},{"issue":"4","key":"10.1016\/j.cvsm.2023.05.011_bib29","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.3390\/ijms23042195","article-title":"Critical evaluation of current hypotheses for the pathogenesis of hypertrophic cardiomyopathy","volume":"23","author":"U\u0161aj","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cvsm.2023.05.011_bib30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fphys.2017.00348","article-title":"Investigations into the sarcomeric protein and Ca2+-regulation abnormalities underlying hypertrophic cardiomyopathy in cats (Felix catus)","volume":"8","author":"Messer","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.cvsm.2023.05.011_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fphys.2018.00243","article-title":"Molecular defects in cardiac myofilament Ca2+-regulation due to cardiomyopathy-linked mutations can be reversed by small molecules binding to troponin","volume":"9","author":"Sheehan","year":"2018","journal-title":"Front Physiol"},{"issue":"20","key":"10.1016\/j.cvsm.2023.05.011_bib32","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1101\/gad.1963910","article-title":"Induced pluripotency: history, mechanisms, and applications","volume":"24","author":"Stadtfeld","year":"2010","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.cvsm.2023.05.011_bib33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"issue":"5903","key":"10.1016\/j.cvsm.2023.05.011_bib34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1164270","article-title":"Generation of mouse induced pluripotent cells without viral vectors","volume":"322","author":"Okita","year":"2008","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.cvsm.2023.05.011_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2183\/pjab.85.348","article-title":"Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome","volume":"85","author":"Fusaki","year":"2009","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"3","key":"10.1016\/j.cvsm.2023.05.011_bib36","doi-asserted-by":"crossref","first-page":"101560","DOI":"10.1016\/j.xpro.2022.101560","article-title":"A\u00a0review of protocols for human iPSC culture, cardiac differentiation, subtype-specification, maturation, and direct reprogramming","volume":"3","author":"Lyra-Leite","year":"2022","journal-title":"STAR Protoc"},{"issue":"5","key":"10.1016\/j.cvsm.2023.05.011_bib37","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cvsm.2023.05.011_bib38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.omtn.2017.05.008","article-title":"Evaluation of MYBPC3 trans-Splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes","volume":"7","author":"Prondzynski","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"10.1016\/j.cvsm.2023.05.011_bib39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00424-018-2173-5","article-title":"Gene therapy strategies in the treatment of hypertrophic cardiomyopathy","volume":"471","author":"Prondzynski","year":"2019","journal-title":"Eur J Physiol"},{"key":"10.1016\/j.cvsm.2023.05.011_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.yjmcc.2020.06.003","article-title":"Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics","volume":"145","author":"Bhagwan","year":"2020","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.cvsm.2023.05.011_bib41","doi-asserted-by":"crossref","first-page":"639699","DOI":"10.3389\/fcell.2021.639699","article-title":"Human iPSCs and genome editing technologies for precision cardiovascular tissue engineering","volume":"9","author":"G\u00e4hwiler","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.cvsm.2023.05.011_bib42","doi-asserted-by":"crossref","first-page":"e003522","DOI":"10.1161\/CIRCGEN.121.003522","article-title":"Human-induced pluripotent stem cell-derived cardiomyocyte model for TNNT2 \u0394160E-induced cardiomyopathy","volume":"15","author":"Kondo","year":"2022","journal-title":"Circ Genom Precis Med"},{"issue":"7","key":"10.1016\/j.cvsm.2023.05.011_bib43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1152\/physiolgenomics.00021.2020","article-title":"Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes","volume":"52","author":"Dainis","year":"2020","journal-title":"Physiol Genomics"},{"issue":"5","key":"10.1016\/j.cvsm.2023.05.011_bib44","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.stemcr.2018.10.006","article-title":"Isogenic pairs of hiPSC-CMs with hypertrophic cardiomyopathy\/LVNC-associated ACTC1 E99K mutation unveil differential functional deficits","volume":"11","author":"Smith","year":"2018","journal-title":"Stem Cell Rep"},{"issue":"4","key":"10.1016\/j.cvsm.2023.05.011_bib45","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.celrep.2015.09.025","article-title":"Contractile defect caused by mutation in MYBPC3 revealed under conditions optimized for human PSC-cardiomyocyte function","volume":"13","author":"Birket","year":"2015","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.cvsm.2023.05.011_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ygeno.2007.04.007","article-title":"A\u00a0substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy","volume":"90","author":"Meurs","year":"2007","journal-title":"Genomics"},{"issue":"2","key":"10.1016\/j.cvsm.2023.05.011_bib47","first-page":"73","article-title":"Association of the myosin binding protein C3 mutation (MYBPC3 R820W) with cardiac death in a survey of 236 Ragdoll cats","volume":"16","author":"Borgeat","year":"2014","journal-title":"J\u00a0Vet Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.cvsm.2023.05.011_bib48","first-page":"S258","article-title":"The influence of clinical and genetic factors on left ventricular wall thickness in Ragdoll cats","volume":"17","author":"Borgeat","year":"2015","journal-title":"J\u00a0Vet Cardiol"},{"issue":"1","key":"10.1016\/j.cvsm.2023.05.011_bib49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.theriogenology.2011.09.022","article-title":"Inducing pluripotency in somatic cells from the snow leopard (Panthera uncia), an endangered felid","volume":"77","author":"Verma","year":"2012","journal-title":"Theriogenology"},{"issue":"1","key":"10.1016\/j.cvsm.2023.05.011_bib50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/biores.2012.0297","article-title":"Nanog Is an essential factor for induction of pluripotency in somatic cells from endangered felids","volume":"2","author":"Verma","year":"2013","journal-title":"Biores Open Access"},{"issue":"19","key":"10.1016\/j.cvsm.2023.05.011_bib51","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1089\/scd.2019.0142","article-title":"Inducing pluripotency in the domestic cat (Felis catus)","volume":"28","author":"Dutton","year":"2019","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.cvsm.2023.05.011_bib52","doi-asserted-by":"crossref","unstructured":"Dutton LC, Dudhia J, Guest DJ. Connolly D.J., CRISPR\/Cas9 genome engineering to model the R820W mutation effects in iPSC-derived cardiomyocytes. Research communications of the 30th ecvim-ca online congress 2-5 September 2020. J Vet Intern Med, 34 (6), 2020, 3058-3166.","DOI":"10.1111\/jvim.15924"},{"issue":"18","key":"10.1016\/j.cvsm.2023.05.011_bib53","first-page":"3231","article-title":"Transcriptome of human foetal heart compared with cardiomyocytes from pluripotent stem cells","volume":"142","author":"van den Berg","year":"2015","journal-title":"Development"},{"key":"10.1016\/j.cvsm.2023.05.011_bib54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.biomaterials.2015.01.067","article-title":"Functional maturation of human pluripotent stem cell derived cardiomyocytes in\u00a0vitro\u2013correlation between contraction force and electrophysiology","volume":"51","author":"Ribeiro","year":"2015","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.cvsm.2023.05.011_bib55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.stemcr.2016.04.006","article-title":"Isolation and mechanical measurements of myofibrils from human induced pluripotent stem cell-derived cardiomyocytes","volume":"6","author":"Pioneer","year":"2016","journal-title":"Stem Cell Rep"},{"issue":"15","key":"10.1016\/j.cvsm.2023.05.011_bib56","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.3390\/ijms20153799","article-title":"Optical investigation of action potential and calcium handling maturation of hiPSC-Cardiomyocytes on biomimetic substrates","volume":"20","author":"Pioner","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cvsm.2023.05.011_bib57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.stemcr.2016.04.011","article-title":"Human engineered heart tissue: analysis of contractile force","volume":"7","author":"Mannhardt","year":"2016","journal-title":"Stem Cell Rep"},{"issue":"19","key":"10.1016\/j.cvsm.2023.05.011_bib58","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.116.024145","article-title":"Defined engineered human myocardium with advanced maturation for applications in heart failure modeling and repair","volume":"135","author":"Tiburcy","year":"2017","journal-title":"Circulation"},{"issue":"7700","key":"10.1016\/j.cvsm.2023.05.011_bib59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41586-018-0016-3","article-title":"Advanced maturation of human cardiac tissue grown from pluripotent stem cells","volume":"556","author":"Ronaldson-Bouchard","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cvsm.2023.05.011_bib60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.yjmcc.2018.03.016","article-title":"Afterload promotes maturation of human induced pluripotent stem cell derived cardiomyocytes in engineered heart tissues","volume":"118","author":"Leonard","year":"2018","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.cvsm.2023.05.011_bib61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yjmcc.2014.05.009","article-title":"Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation","volume":"74","author":"Hirt","year":"2014","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.cvsm.2023.05.011_bib62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.biomaterials.2016.09.024","article-title":"Dynamic culture yields engineered myocardium with near-adult functional output","volume":"111","author":"Jackman","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.cvsm.2023.05.011_bib63","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijcard.2018.08.069","article-title":"Fatty acid metabolism driven mitochondrial bioenergetics promotes advanced developmental phenotypes in human induced pluripotent stem cell derived cardiomyocytes","volume":"272","author":"Ramachandra","year":"2018","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.cvsm.2023.05.011_bib64","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41467-017-01946-x","article-title":"Cardiopatch platform enables maturation and scaleup of human pluripotent stem cell-derived engineered heart tissues","volume":"8","author":"Shadrin","year":"2017","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.cvsm.2023.05.011_bib65","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/CIRCULATIONAHA.114.014998","article-title":"Mechanical stress conditioning and electrical stimulation promote contractility and force maturation of induced pluripotent stem cell-derived human cardiac tissue","volume":"134","author":"Ruan","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.cvsm.2023.05.011_bib66","doi-asserted-by":"crossref","first-page":"e001974","DOI":"10.1161\/CIRCGENETICS.117.001974","article-title":"Proteomic analysis of the myocardium in hypertrophic obstructive cardiomyopathy","volume":"11","author":"Coats","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"13","key":"10.1016\/j.cvsm.2023.05.011_bib67","first-page":"1820","article-title":"Role of the lysyl oxidase enzyme family in cardiac function and disease","volume":"115","author":"Al-U'datt","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cvsm.2023.05.011_bib68","doi-asserted-by":"crossref","first-page":"13710","DOI":"10.1038\/ncomms13710","article-title":"Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment","volume":"7","author":"Yang","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.cvsm.2023.05.011_bib69","doi-asserted-by":"crossref","unstructured":"Cheng WC, Wilkie L, Dobromylsky M, et al. Cellular localization of key proteins controlling pro-fibrotic pathways in cats with hypertrophic cardiomyopathy 2020 ACVIM Forum On Demand Research Abstract Program. J Vet Intern Med, 34 (6), 2020, 2830-2989. https:\/\/doi.org\/10.1111\/jvim.15904.","DOI":"10.1111\/jvim.15904"},{"issue":"11","key":"10.1016\/j.cvsm.2023.05.011_bib70","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3390\/ijms19113361","article-title":"Many cells make life work-multicellularity in stem cell-based cardiac disease modelling","volume":"19","author":"Wang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cvsm.2023.05.011_bib71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3389\/fcvm.2018.00143","article-title":"Heterocellularity and cellular cross-talk in the cardiovascular system","volume":"5","author":"Perbellini","year":"2018","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.cvsm.2023.05.011_bib72","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/CIRCRESAHA.118.313089","article-title":"Myofibroblast-specific TGF\u03b2 receptor II signaling in the fibrotic response to cardiac myosin binding protein c-induced cardiomyopathy","volume":"123","author":"Meng","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.cvsm.2023.05.011_bib73","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.actbio.2019.03.017","article-title":"Cardiomyocytes facing fibrotic conditions re-express extracellular matrix transcripts","volume":"89","author":"Heras-Bautista","year":"2019","journal-title":"Acta Biomater"},{"issue":"11","key":"10.1016\/j.cvsm.2023.05.011_bib74","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJMc1915189","article-title":"Reversal of TGF\u03b21- driven profibrotic state in patients with pulmonary fibrosis","volume":"382","author":"Chapman","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cvsm.2023.05.011_bib75","doi-asserted-by":"crossref","first-page":"709819","DOI":"10.3389\/fphar.2021.709819","article-title":"Azithromycin attenuates bleomycin-induced pulmonary fibrosis partly by inhibiting the expression of LOX and LOXL-2","volume":"12","author":"Tong","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.cvsm.2023.05.011_bib76","doi-asserted-by":"crossref","first-page":"e13659","DOI":"10.1111\/acel.13659","article-title":"Lysyl oxidase-like 2 inhibitor rescues D-galactose-induced skeletal muscle fibrosis","volume":"21","author":"Wu","year":"2022","journal-title":"Aging Cell"},{"issue":"2","key":"10.1016\/j.cvsm.2023.05.011_bib77","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000518526","article-title":"LOXL2 inhibitor attenuates angiotensin II-induced atrial fibrosis and vulnerability to atrial fibrillation through inhibition of transforming growth factor beta-1 Smad2\/3 pathway","volume":"51","author":"Wu","year":"2022","journal-title":"Cerebrovasc Dis"},{"issue":"10","key":"10.1016\/j.cvsm.2023.05.011_bib78","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.3390\/ijms23105533","article-title":"Pan-lysyl oxidase inhibitor PXS-5505 ameliorates multiple-organ fibrosis by inhibiting collagen crosslinks in rodent models of systemic sclerosis","volume":"23","author":"Yao","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.cvsm.2023.05.011_bib79","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.31236","article-title":"Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis","volume":"72","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cvsm.2023.05.011_bib80","series-title":"Ch 4 the contractile proteins","first-page":"88","article-title":"Physiology of the heart","author":"Katz","year":"2010"},{"key":"10.1016\/j.cvsm.2023.05.011_bib81","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.cvsm.2023.05.011_bib82","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10253","key":"10.1016\/j.cvsm.2023.05.011_bib83","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.cvsm.2023.05.011_bib84","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.cvsm.2023.05.011_bib85","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41598-022-26630-z","article-title":"Effects of aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy","volume":"13","author":"Sharpe","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.cvsm.2023.05.011_bib86","unstructured":"FDA. FDA approves new drug to improve heart function in adults with rare heart condition. Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition. Accessed February 15, 2023."},{"key":"10.1016\/j.cvsm.2023.05.011_bib87","unstructured":"Cytokinetics. Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Available at: https:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-announces-start-sequoia-hcm-phase-3-clinical-trial. Accessed February 15, 2023."},{"issue":"6273","key":"10.1016\/j.cvsm.2023.05.011_bib88","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A\u00a0small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.cvsm.2023.05.011_bib89","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cvsm.2010.04.004","article-title":"Feline hypertrophic cardiomyopathy: an update","volume":"40","author":"Abbott","year":"2010","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"10.1016\/j.cvsm.2023.05.011_bib90","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cvsm.2023.05.011_bib91","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/gerona\/glw090","article-title":"Rapamycin: an inhibitor of aging emerges from the soil of easter island","volume":"71","author":"Apelo","year":"2016","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"10.1016\/j.cvsm.2023.05.011_bib92","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cvsm.2023.05.011_bib93","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/CIRCRESAHA.117.311147","article-title":"New insights into the role of mTOR signaling in the cardiovascular system","volume":"122","author":"Sciarretta","year":"2018","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.cvsm.2023.05.011_bib94","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000057979.36322.88","article-title":"Rapamycin attenuates load-induced cardiac hypertrophy in mice","volume":"107","author":"Shioi","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cvsm.2023.05.011_bib95","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1172\/JCI44972","article-title":"Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation","volume":"121","author":"Marin","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cvsm.2023.05.011_bib96","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1161\/01.CIR.0000130641.08705.45","article-title":"Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload","volume":"109","author":"McMullen","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cvsm.2023.05.011_bib97","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.ajkd.2008.04.018","article-title":"Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial","volume":"52","author":"Paoletti","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cvsm.2023.05.011_bib98","unstructured":"Stern JA et\u00a0al. Oral Rapamycin Therapy in Feline Subclinical Hypertrophic Cardiomyopathy: Results of the RAPACAT Clinical Trial. Proceedings of the International Cardio-renal Veterinary Symposium (ICVS) Americas 2022. Presented October 16, 2022. Fort Lauderdale, FL."}],"container-title":["Veterinary Clinics of North America: Small Animal Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195561623000840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195561623000840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T01:50:18Z","timestamp":1759283418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0195561623000840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0195561623000840"],"URL":"https:\/\/doi.org\/10.1016\/j.cvsm.2023.05.011","relation":{},"ISSN":["0195-5616"],"issn-type":[{"value":"0195-5616","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing Treatments for Feline Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Veterinary Clinics of North America: Small Animal Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cvsm.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}